Skip to Main Content

Thomas Prebet, MD, PhD

Associate Professor Adjunct

Contact Information

Thomas Prebet, MD, PhD

Patient Care Location

Mailing Address

  • Hematology

    333 Cedar Street, PO Box 208028

    New Haven, CT 06520-8028

    United States



After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.

Education & Training

  • Post-Doctoral Fellow
    Johns Hopkins University (2010)
  • PhD
    Centre de Recherche en Cancerologie (2009)
  • MS
    Claude Bernard University (2005)
  • Resident
    University Hospitals of Lyon (2004)
  • MD
    Montpellier University (2000)


  • Management of Elderly AML
    Paris, France 2019
  • ASH 2015 highlights in acute myeloid leukemia
    Omaha, United States 2016
  • Trends in clinical development in myelodysplastic syndromes
    Houston, United States 2015
  • Myelodysplastic syndromes: Challenges of second
    Tampa, United States 2015
  • Supportive care for myelodysplastic syndromes in 2015 line treatments
    Washington, United States 2015
  • Outcome of patients treated for MDS after failure of lenalidomide therapy
    Orlando, United States 2015
  • Current treatment strategies in MDS
    Marseille, France 2014
  • MDS: State of the art in 2014
    Marseille, France 2014
  • High risk MDS: Clinical management after frontline treatment failure
    Dresden, Germany 2014
  • Chemo-genomic approaches in AML
    Paris, France 2014
  • Second line treatments in high risk MDS
    Avignon, France 2014
  • Elderly high risk MDS: treatment options and supportive care recommendations
    Aix-en-Provence, France 2013
  • Ongoing and futures trials in myelodysplastic syndromes
    Aix-en-Provence, France 2013
  • AML 2013: State of the art” and “MDS 2013: state of the art
    Marseille, France 2013
  • Investigational approaches in high risk MDS: second line treatments
    Paris, France 2013
  • High risk MDS: second line options
    Paris, France 2013
  • Cancer biomarkers and woman fertility preservation
    Lyon, France 2012
  • Implication of PTK7 receptor in AML
    London, United Kingdom 2012
  • Outcome of MDS patients with hypomethylating agent failure
    Dresden, Germany 2012
  • Clinical trials in myelodysplastic syndromes
    Aix-en-Provence, France 2011
  • Hypomethylating agent failure
    Houston, United States 2011
  • Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
    Orlando, United States 2010
  • Outcome of patients treated for high risk MDS after azacitidine failure
    Orlando, United States 2010
  • Combination of gemtuzumab and high dose cytarabine for first relapse AML
    Paris, France 2009
  • Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup
    Atlanta, United States 2008

Honors & Recognition

AwardAwarding OrganizationDate
Award from association Laurette FugainSociété Française d’hématologie2012
Award from French transfusion medicine societyassociation recherche transfusion/ société Française de Transfusion Sanguine2011

Professional Service

Inpatient Hospitalist Sub-CommitteeCo-Chair2019 - Present
Inpatient Re-Organization Project Steering CommitteeMember2019 - Present
Data and Safety Monitoring Board, Elderly French CLL Intergroup StudyMember2019 - Present
Data and Safety Monitoring Board, French National AML TrialChair2019 - Present
Data and Safety Monitoring Board, French National AML TrialMember2018 - 2019
Smilow Telehealth InitiativesParticipant2018 - Present
Yale Biological Safety Committee, Human Gene Therapy SubcommitteeMember2018 - Present
Yale Cancer Center Chief Medical Officer Search CommitteeMember2018 - Present
Yale Cancer Center Clinical Trial Office Search CommitteeMember2018 - Present
Yale Affiliated Hospital ProgramLecturer2018 - Present
Via Pathway OncologyCo-Chair2018 - Present
National Comprehensive Cancer NetworkCommittee Member2018 - Present
National Cancer Center NetworkAML committee2017 - Present
Yale Cancer Center CROC CommitteeMember2017 - Present
Yale Cancer Center CAR-T CommitteeMember2017 - Present
Yale Cancer Center Process & Operations CommitteeMember2017 - Present
Yale-New Haven Hospital Duffy ServiceChairperson2017 - Present
Yale Cancer Center Hematology Clinical Trial OfficeDirector2017 - Present
Yale Cancer Center IRB CommitteeMember2017 - Present
Yale Human Research Protection ProgramHuman Investigation Committee2016 - Present
Yale School of Medicine Hematology/Oncology Fellowship ProgramInterviewer2016 - Present
Yale School of Medicine Internal Medicine Residency ProgramInterviewer2016 - Present
Yale Human Research Protection Committee, HIC 1Member2016 - Present
Onco hematology for French regional cancer grant program (PHRC regional)Member2013 - 2015
Onco hematology for French regional cancer grant program (PHRC regional)Scientific Advisor2013 - 2015
Onco Hematology for Fullbright commission (French American scholar exchange commission)Member2011 - Present
Onco Hematology for Fullbright commission (French American scholar exchange commission)Scientific Advisor2011 - Present
American Society of HematologyReviewer2010 - 2019
French NIH (AFFSAPS and ANSM)Reviewer2009 - 2019
French regional cancer research agencies (CANCEROPOLE) for Paris, Lyon, and MarseilleReviewer2009 - 2019
New England Journal of MedicineReviewer2009 - Present
BloodReviewer2009 - Present
LeukemiaReviewer2009 - Present
CancerReviewer2009 - Present
DrugsReviewer2009 - Present
HematologicaReviewer2009 - Present
TransfusionReviewer2009 - Present
EpigeneticsReviewer2009 - Present
British Journal of HematologyReviewer2009 - Present

Departments & Organizations